symbol |
LENS |
会社名 | Presbia PLC (プレスビア) |
分野(sector) |
Health Care
ヘルスケア
|
産業(industry) |
Medical/Dental Instruments
|
業種 |
先端医療機器_テクノロジ―
医療関連(Health Care)
|
概要 |
事業概要 Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia the age-related loss of the ability to focus on near objects. The Company's segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States. The Company's lens referred to as the microlens is a miniature lens designed to be surgically implanted in a patient's eye to improve that patient's ability to see objects at close distances. The microlens is a disc shaped lens that has a refractive zone in the periphery designed to improve near vision problems associated with presbyopia and a central zone that is designed to improve distance vision. The Company's solution is a standalone solution for plano presbyopes or those individuals suffering from presbyopia but do not have any other visual disorders. プレスビアはアイルランドの工学レンズのインプラント会社。主に老眼矯正レンズを扱う。同社の老眼矯正用レンズPresbia Flexivue Microlensは直径3mmの小型レンズで、フェムト秒レ―ザによって作成された角膜ポケットに移植され、交換、取り外し可能なように設計されている。 Operates as an ophthalmic device company
|
本社所在地 | Suite 7 Sandyford Office Centre 17 Corrig Road Sandyford Dublin 18 IRL |
代表者氏名 | Mark T. Yung Mark T. Yung |
代表者役職名 | Executive Chairman of the Board 取締役会長 |
電話番号 | +353 1-551-1487 |
設立年月日 | 41671 |
市場名 | NASDAQ Small Cap |
ipoyear | 2015年 |
従業員数 | 24人 |
url | www.presbia.com |
nasdaq_url | https://www.nasdaq.com/symbol/lens |
adr_tso | ― |
EBITDA | EBITDA(百万ドル) -11.40900 |
終値(lastsale) | 1.72 |
時価総額(marketcap) | 29579104.88 |
時価総額 | 時価総額(百万ドル) 20.93174 |
売上高 | 売上高(百万ドル) 0.01500 |
企業価値(EV) | 企業価値(EV)(百万ドル) 18.08574 |
当期純利益 | 当期純利益(百万ドル) -11.93700 |
決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Presbia PLC revenues increased 20% to $6K. Net loss decreased 53% to $4.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development decrease of 56% to $1.7M (expense) General and administrative decrease of 48% to $1.8M (expense) Sales and marketing decrease of 60% to $713K (expense). |